Norway's COVID vaccine chief Are Stuwitz Berg dies at 53 after long illness
Are Stuwitz Berg, the Norwegian physician who led the country's COVID-19 vaccine rollout, has died at 53 after a prolonged illness, according to the public health institute FHI
Tired of too many ads?
Remove Ads
Leadership during crisis
Tired of too many ads?
Remove Ads
Are Stuwitz Berg , the senior physician who led Norway 's national COVID-19 vaccination campaign and spent decades advancing public health, has died at the age of 53 after a prolonged illness, according to the Norwegian Institute of Public Health (FHI).Berg served as department director and chief physician at FHI, where he became a prominent figure during the pandemic. He was often seen on national television, calmly explaining the science behind vaccines and guiding Norway through one of its most challenging public health crises. He is survived by his wife and three children.Though officials have not released a specific cause of death, his colleagues confirmed that he had been battling a serious illness for several months.During the pandemic, Berg oversaw the rollout of COVID-19 vaccines across Norway, including managing logistics, communicating with international health partners, and addressing public skepticism. He was widely recognized for his transparent approach and efforts to build trust in science.Berg was known not only for his leadership during COVID-19 but also for his lifelong dedication to pediatric medicine. Earlier in his career, he worked in Oslo hospitals and spent time in Tanzania providing medical care to underserved communities.Berg had previously acknowledged that vaccines, like any medical intervention, can carry rare side effects, particularly in younger populations, but he consistently stood by their overall safety and effectiveness.Following his death, some online platforms have circulated unverified claims linking his passing to the COVID-19 vaccines he helped deploy. Norwegian authorities and mainstream media have not supported those claims. No medical or official sources have confirmed any link between Berg's death and vaccination.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 hours ago
- Economic Times
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions. Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
Time of India
9 hours ago
- Time of India
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions . Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity CXO others Public Policy Healthcare Digital Marketing Degree MBA Artificial Intelligence Others PGDM Data Science Data Analytics Product Management MCA Operations Management Leadership Design Thinking Project Management Finance Management healthcare Technology Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details Q. What are melanoma cells by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. Live Events This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites. Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine? A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines. The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding. According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program. Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
The contagion scale: From measles to TB which disease spread fastest?
When the Covid pandemic hit, many people turned to the eerily prescient film Contagion (2011) for answers – or at least for catharsis. Suddenly, its hypothetical plot felt all too real. Applauded for its scientific accuracy, the film offered more than suspense – it offered lessons. One scene in particular stands out. Kate Winslet's character delivers a concise lesson on the infectious power of various pathogens – explaining how they can be spread from our hands to the many objects we encounter each day – 'door knobs, water fountains, elevator buttons and each other'. These everyday objects, known as fomites, can become silent vehicles for infection. She also considered how each infection is given a value called R0 (or R-nought) based on how many other people are likely to become infected from another. So, for an R0 of two, each infected patient will spread the disease to two others. Who will collectively then give it to four more. And so a breakout unfolds. The R0 measure indicates how an infection will spread in a population. If it's greater than one (as seen above), the outcome is disease spread. An R0 of one means the level of people being infected will remain stable, and if it's less than one, the disease will often die out with time. Circulating infections spread through a variety of routes and differ widely in how contagious they are. Some are transmitted via droplets or aerosols – such as those released through coughing or sneezing – while others spread through blood, insects (like ticks and mosquitoes), or contaminated food and water. But if we step back to think about how we can protect ourselves from developing an infectious disease, one important lesson is in understanding how they spread. And as we'll see, it's also a lesson in protecting others, not just ourselves. Here is a rundown of some of the most and least infectious diseases on the planet. In first place for most contagious is measles. Measles has made a resurgence globally in recent years, including in high-income countries like the UK and US. While several factors contribute to this trend, the primary cause is a decline in childhood vaccination rates. This drop has been driven by disruptions such as the Covid pandemic and global conflict, as well as the spread of misinformation about vaccine safety. The R0 number for measles is between 12 and 18. If you do the maths, two cycles of transmission from that first infected person could lead to 342 people catching the illness. That's a staggering number from just one patient – but luckily, the protective power of vaccination helps reduce the actual spread by lowering the number of people susceptible to infection. Measles is extraordinarily virulent, spreading through tiny airborne particles released during coughing or sneezing. It doesn't even require direct contact. It's so infectious that an unvaccinated person can catch the virus just by entering a room where an infected person was present two hours earlier. People can also be infectious and spread the virus before they develop symptoms or have any reason to isolate. Other infectious diseases with high R0 values include pertussis, or whooping cough (12 to 17), chickenpox (ten to 12), and Covid, which varies by subtype but generally falls between eight and 12. While many patients recover fully from these conditions, they can still lead to serious complications, including pneumonia, seizures, meningitis, blindness, and, in some cases, death. Low spread, high stakes At the other end of the spectrum, a lower infectivity rate doesn't mean a disease is any less dangerous. Take tuberculosis (TB), for example, which has an R0 ranging from less than one up to four. This range varies depending on local factors like living conditions and the quality of available healthcare. Caused by the bacterium] Mycobacterium tuberculosis, TB is also airborne but spreads more slowly, usually requiring prolonged close contact with someone with the active disease. Outbreaks tend to occur among people who share living spaces – such as families, households, and in shelters or prisons. The real danger with TB lies in how difficult it is to treat. Once established, it requires a combination of four antibiotics taken over a minimum of six months. Standard antibiotics like penicillin are ineffective, and the infection can spread beyond the lungs to other parts of the body, including the brain, bones, liver and joints. What's more, cases of drug-resistant TB are on the rise, where the bacteria no longer respond to one or more of the antibiotics used in treatment. Other diseases with lower infectivity include Ebola – which is highly fatal but spreads through close physical contact with bodily fluids. Its R0 ranges from 1.5 to 2.5. Diseases with the lowest R0 values – below one – include Middle East respiratory syndrome (Mers), bird flu and leprosy. While these infections are less contagious, their severity and potential complications should not be underestimated. The threat posed by any infectious disease depends not only on how it affects the body, but also on how easily it spreads. Preventative measures like immunisation play a vital role – not just in protecting people, but also in limiting transmission to those who cannot receive some vaccinations – such as infants, pregnant women and people with severe allergies or weakened immune systems. These individuals are also more vulnerable to infection in general. This is where herd immunity becomes essential. By achieving widespread immunity within the population, we help protect people who are most susceptible.
